ReviewInfection and drug resistance2021
Appropriate Use of Ceftriaxone in Sub-Saharan Africa: A Systematic Review.
Review in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Inappropriate antibiotic prescribing in Ethiopian hospitals: a systematic review.International journal of clinical pharmacy · 2026Pooled it
- Antimicrobial resistance in community-acquired enteric pathogens among children aged ≤ 10-years in low-and middle-income countries: a systematic review and meta-analysis.Frontiers in microbiology · 2025Pooled it
- Inappropriate antibiotic utilization in hospitalized patients in Ethiopia: A systematic review and meta-analysis.Exploratory research in clinical and social pharmacy · 2026Review
- Prevalence of antimicrobial resistance in acute community-acquired urinary tract infections in Sub-Saharan Africa: a systematic review.JAC-antimicrobial resistance · 2026Review
- Evaluation of Ceftriaxone Utilization in Three Regional Referral Hospitals in Uganda: A Prospective Multicentre Study.Infection and drug resistance · 2026Article
- Observational
- Antimicrobial Usage Among Acutely Ill Hospitalized Children Aged 2‒23 Months in Sub-Saharan Africa and South Asia.Open forum infectious diseases · 2025Article
- Antibiotic susceptibility patterns of bacterial uropathogens at a private tertiary hospital in Uganda: a retrospective study.BMC infectious diseases · 2025Article
- High Prevalence of Antimicrobial Prescribing Among Public Health Facilities in Central Uganda: Findings from Point Prevalence Survey.Infection and drug resistance · 2025Article
- Antimicrobial use in hospitalized patients: a point prevalence survey across four tertiary hospitals in Niger.JAC-antimicrobial resistance · 2024Article
- Aligning antimicrobial resistance surveillance with schistosomiasis research: an interlinked One Health approach.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2024Review
- Antibiotic therapy for bacterial pneumonia.Journal of pharmaceutical health care and sciences · 2024Review
- The Use of Antibiotics at the End of Life: A Cross-Sectional Study.Health services insights · 2024Article
- Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia.Antibiotics (Basel, Switzerland) · 2022Article
- Implementation of an antimicrobial stewardship programme in three regional hospitals in the south-east of Liberia: lessons learned.JAC-antimicrobial resistance · 2022Article
- Assessing antibiotic utilization among pediatric patients in Gaborone, Botswana.SAGE open medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCeftriaxone is the most frequently used antibiotic for the treatment of various bacterial infections in hospitalized and ambulatory patients. Despite this, inappropriate ceftriaxone use is common.
objectiveThe aim of this review is to assess the appropriate use of ceftriaxone in sub-Saharan African countries.
methodsA systematic search was done on PubMed, EMBASE, Cochrane Libraries and Google Scholar for papers published addressing the prescribing pattern and use of ceftriaxone in sub-Saharan Africa. The findings were reported in medians and quartiles.
resultsA total of 15 articles met the inclusion criteria. Pneumonia and sepsis were the most frequently diagnosed infections in the included studies. The overall median prevalence of appropriate ceftriaxone use is 39.2% (IQR: 29.9-60.9), showing that most of the included studies reported a higher prevalence of inappropriate ceftriaxone use. Although there are a higher number of patients with inappropriate use of ceftriaxone, a relatively higher number of patients got appropriate daily dose (79.8%, IQR: 45.7-89.4) of ceftriaxone than appropriate duration of ceftriaxone (55%, IQR: 52.2-80).
conclusionThe review revealed that three in five patients with ceftriaxone got inappropriate ceftriaxone's dose, frequency or duration. A relatively higher number of patients got appropriate daily dose of ceftriaxone. On the other hand, approximately more than half of the patients got inappropriate duration, too short or too long, of ceftriaxone. Hence, prescribers are recommended to adhere to their country-specific treatment guideline. Moreover, it is highly recommended to either commence or strengthen antimicrobial stewardship program effectively in their healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.